Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Effectiveness of DOlutegravir/Lamivudine Compared With Bictegravir/Tenofovir Alafenamide/Emtricitabine in People Living With HIV Without Antiretroviral Experience (TEOTL)

NCT07031063 is registered in ClinicalTrials.gov with Instituto Mexicano del Seguro Social as lead sponsor.

NCT NCT07031063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07031063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Effectiveness of DOlutegravir/Lamivudine Compared With Bictegravir/Tenofovir Alafenamide/Emtricitabine in People Living With HIV Without Antiretroviral Experience (TEOTL)
Lead sponsor
Instituto Mexicano del Seguro Social
Phase
Phase 4
Overall status
Recruiting
Start date
April 1, 2025
Completion date
December 1, 2028
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiretroviral treatment, hiv infection, metabolic syndrome